| Title |
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
|
|---|---|
| Published in |
Aging Clinical and Experimental Research, January 2016
|
| DOI | 10.1007/s40520-015-0522-1 |
| Pubmed ID | |
| Authors |
Cyrus Cooper, Thomas Bardin, Maria-Luisa Brandi, Patrice Cacoub, John Caminis, Roberto Civitelli, Maurizio Cutolo, Willard Dere, Jean-Pierre Devogelaer, Adolfo Diez-Perez, Thomas A. Einhorn, Patrick Emonts, Olivier Ethgen, John A. Kanis, Jean-Marc Kaufman, Tore K. Kvien, Willem F. Lems, Eugene McCloskey, Pierre Miossec, Susanne Reiter, Johann Ringe, René Rizzoli, Kenneth Saag, Jean-Yves Reginster |
| Abstract |
This consensus review article considers the question of whether glucocorticoid (GC) therapy is still relevant in the treatment of rheumatic diseases, with a particular focus on rheumatoid arthritis (RA), and whether its side effects can be adequately managed. Recent basic and clinical research on the molecular, cellular and clinical effects of GCs have considerably advanced our knowledge in this field. An overview of the subject seems appropriate. This review is the result of a multidisciplinary expert working group, organised by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. The recent literature was surveyed and the salient evidence synthetized. The pathophysiological basis of RA (and other inflammatory rheumatic diseases) now strongly implicates the adaptive immune system in addition to innate mechanisms. The molecular effect of GCs and differential GC sensitivity is better understood, although exploiting this knowledge is still in its infancy. The newer treatment strategies of early and aggressive control of RA have gr eatly improved clinical outcomes, but improvements are still possible. Newer targeted anti-inflammatory drugs have made an important impact, yet they too are associated with numerous side effects. Short durations of moderate doses of GCs are generally well tolerated and have a positive benefit/risk ratio. Patients should be assessed for fracture risk and bone preserving agents and be prescribed calcium and vitamin D supplementation. Within a strategy of a disease modifying approach to inflammatory disease, combination therapy including a GC is effective approach. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 1% |
| Unknown | 80 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 15% |
| Student > Ph. D. Student | 9 | 11% |
| Student > Master | 9 | 11% |
| Professor | 8 | 10% |
| Student > Bachelor | 8 | 10% |
| Other | 18 | 22% |
| Unknown | 17 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 31% |
| Nursing and Health Professions | 10 | 12% |
| Agricultural and Biological Sciences | 10 | 12% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 7 | 9% |
| Unknown | 21 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2016.
All research outputs
#22,778,604
of 25,394,764 outputs
Outputs from Aging Clinical and Experimental Research
#1,706
of 1,868 outputs
Outputs of similar age
#342,143
of 400,219 outputs
Outputs of similar age from Aging Clinical and Experimental Research
#19
of 22 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,868 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,219 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.